Sanofi (SNW2) - Total Assets
Based on the latest financial reports, Sanofi (SNW2) holds total assets worth €129.79 Billion EUR (≈ $151.74 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sanofi - Total Assets Trend (2016–2024)
This chart illustrates how Sanofi's total assets have evolved over time, based on quarterly financial data. Also see SNW2 stock market capitalisation for the company's overall valuation and market capitalisation.
Sanofi - Asset Composition Analysis
Current Asset Composition (December 2024)
Sanofi's total assets of €129.79 Billion consist of 32.1% current assets and 67.9% non-current assets. Review total liabilities of Sanofi to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 5.6% |
| Accounts Receivable | €7.68 Billion | 5.8% |
| Inventory | €9.43 Billion | 7.1% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €22.63 Billion | 17.0% |
| Goodwill | €43.38 Billion | 32.7% |
Asset Composition Trend (2016–2024)
This chart illustrates how Sanofi's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Sanofi stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sanofi's current assets represent 32.1% of total assets in 2024, an increase from 31.6% in 2016.
- Cash Position: Cash and equivalents constituted 5.6% of total assets in 2024, down from 9.8% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 49.0% of total assets, an increase from 48.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 32.7% of total assets.
Sanofi Competitors by Total Assets
Key competitors of Sanofi based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pfizer Inc
NYSE:PFE
|
USA | $201.13 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $136.46 Billion |
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
AstraZeneca PLC
MX:AZNN
|
Mexico | MX$114.07 Billion |
|
Novartis AG ADR
NYSE:NVS
|
USA | $122.03 Billion |
|
AstraZeneca PLC
F:ZEGA
|
Germany | €114.46 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $32.09 Billion |
Sanofi - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.06 | 1.00 | 1.42 |
| Quick Ratio | 0.30 | 0.65 | 1.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.94 Billion | €54.00 Million | €8.55 Billion |
Sanofi - Advanced Valuation Insights
This section examines the relationship between Sanofi's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.41 |
| Latest Market Cap to Assets Ratio | 0.80 |
| Asset Growth Rate (YoY) | 5.0% |
| Total Assets | €132.80 Billion |
| Market Capitalization | $105.64 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Sanofi's assets below their book value (0.80x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Sanofi's assets grew by 5.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Sanofi (2016–2024)
The table below shows the annual total assets of Sanofi from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €132.80 Billion ≈ $155.25 Billion |
+5.01% |
| 2023-12-31 | €126.46 Billion ≈ $147.85 Billion |
+1.51% |
| 2022-12-31 | €124.58 Billion ≈ $145.65 Billion |
+3.61% |
| 2021-12-31 | €120.24 Billion ≈ $140.58 Billion |
+4.99% |
| 2020-12-31 | €114.53 Billion ≈ $133.90 Billion |
+1.59% |
| 2019-12-31 | €112.74 Billion ≈ $131.80 Billion |
+1.19% |
| 2018-12-31 | €111.41 Billion ≈ $130.25 Billion |
+11.60% |
| 2017-12-31 | €99.83 Billion ≈ $116.71 Billion |
-4.63% |
| 2016-12-31 | €104.67 Billion ≈ $122.37 Billion |
-- |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting aga… Read more